SOUTH KOREA · OPENDART
PharmaResearch Co., Ltd.
파마리서치 · 214450 · KOSDAQ · Healthcare · Biotechnology
Score
Not ranked: no net buying on the exchange by an individual insider in the last 180 days.
Insiders' buying price vs the latest close
Insiders paid 301,784.71 KRW a share on average (3 purchase lines, 2 buyers, 2026-02-09 – 2026-04-02). The close on 2026-10-16 was 7.9% below that price.
The latest purchase (2026-04-02) was at 290,714.00 KRW; the close was 4.4% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | YI HWAN KIM | Division head | Bought on the exchange | 350 | ₩290,714 | ₩101.7M | DART ↗ |
| 2026-02-10 | KwanSik Youn | Senior managing director | Bought on the exchange | 5 | ₩334,500 | ₩1.7M | DART ↗ |
| 2026-02-09 | KwanSik Youn | Senior managing director | Bought on the exchange | 75 | ₩351,267 | ₩26.3M | DART ↗ |
| 2025-10-28 | Jung Rae Jun | Managing director | Sold on the exchange | 500 | ₩536,000 | ₩268.0M | DART ↗ |
Other changes in holdings · 4
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-01-01 | YongSun Yu | Managing director | New appointment(+) | 132 | DART ↗ |
| 2025-03-25 | Jung Rae seung | Inside director | New appointment(+) | 10,000 | DART ↗ |
| 2025-03-25 | Jung Rae Jun | Managing director | New appointment(+) | 1,780 | DART ↗ |
| 2024-10-09 | Polish Company Limited | Major shareholder | 제3자배정유상증자(+) | 1,175,647 | DART ↗ |